• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Arena Pharmaceuticals Inc.

    3/11/22 9:01:59 AM ET
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARNA alert in real time by email
    POS AM 1 brhc10035056_s-3posam.htm S-3 POS AM
    Registration No. 333-112542
    Registration No. 333-136023
    Registration No. 333-160983
    Registration No. 333-167498


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    Post-Effective Amendment No. 1
    to
    FORM S-3 REGISTRATION STATEMENT NO. 333-112542
    FORM S-3 REGISTRATION STATEMENT NO. 333-136023
    FORM S-3 REGISTRATION STATEMENT NO. 333-160983
    FORM S-3 REGISTRATION STATEMENT NO. 333-167498
    UNDER
    THE SECURITIES ACT OF 1933



    Arena Pharmaceuticals, Inc.
    (Exact name of registrant as specified in its charter)



    Delaware
     
    23-2908305
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S Employer
    Identification Number)

    135 Heber Avenue, Suite 204
    Park City, UT 84060
    (858) 453-7200
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)



    Margaret Madden
    Vice President and Secretary
    Arena Pharmaceuticals, Inc.
    235 East 42nd Street
    New York, NY 10017
    (212) 733-2323

    (Name, address, including zip code, and telephone number, including area code, of agent for service)




    Copies to:
    Emily Oldshue
    Ropes & Gray LLP
    Prudential Tower
    800 Boylston Street
    (617) 951-7241
     

     
    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.
     
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  ☐
     
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐
     
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☒
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
           
       
    Emerging growth company
    ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐



    EXPLANATORY NOTE
     
    DEREGISTRATION OF SECURITIES
     
    This Post-Effective Amendment No. 1 relates to the following Registration Statements filed by Arena Pharmaceuticals, Inc., a Delaware corporation (the “Registrant” or the “Company”) on Form S-3 (collectively, the “Registration Statements”).
     

    •
    Registration Statement No. 333-112542, filed with the Securities and Exchange Commission (the “SEC”) on February 6, 2004, as amended on March 18, 2004, April 13, 2004 and April 20, 2004, relating to the registration by the Company of 11,227,933 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”);
     

    •
    Registration Statement No. 333-136023, filed with the SEC on July 25, 2006, relating to the registration by the Company of 829,856 shares of Common Stock;
     

    •
    Registration Statement No. 333-160983, filed with the SEC on August 3, 2009, relating to the registration by the Company of 28,000,000 shares of Common Stock; and
     

    •
    Registration Statement No. 333-167498, filed with the SEC on June 14, 2010, relating to the registration by the Company of 27,200,000 shares of Common Stock.
     
    On March 11, 2022, pursuant to the Agreement and Plan of Merger, dated as of December 12, 2021 (the “Merger Agreement”), by and among the Company, Pfizer Inc., a Delaware corporation (“Parent”), and Antioch Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
     
    As a result of the consummation of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on March 11, 2022.

     
    ARENA PHARMACEUTICALS, INC.
         
     
    By:
    /s/ Margaret Madden
       
    Margaret Madden
       
    Vice President and Secretary
     
    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements.



    Get the next $ARNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARNA

    DatePrice TargetRatingAnalyst
    2/9/2022$120.00 → $100.00Buy → Neutral
    HC Wainwright & Co.
    12/21/2021$93.00 → $100.00Overweight → Neutral
    Cantor Fitzgerald
    12/14/2021Market Outperform → Market Perform
    JMP Securities
    12/14/2021$112.00 → $100.00Outperform → Market Perform
    SVB Leerink
    12/14/2021$76.00 → $100.00Outperform → Sector Perform
    RBC Capital
    12/14/2021$98.00 → $100.00Outperform → Neutral
    Credit Suisse
    12/14/2021$100.00Buy → Hold
    Jefferies
    12/13/2021Buy → Hold
    Needham
    More analyst ratings

    $ARNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte

      2/17/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arena Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously

      2/9/22 6:14:57 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously

      12/21/21 5:12:52 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by JMP Securities

      JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform

      12/14/21 7:04:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Nova Tina Susan disposed of 20,843 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:43 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Fetzer Oliver disposed of 9,692 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:23 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gallahue Kieran disposed of 12,911 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:23:59 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Arena Pharmaceuticals Inc.

      15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/21/22 6:03:29 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:11 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:08 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ARNA
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/11/22 10:07:09 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/9/22 3:24:50 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/4/22 9:26:03 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt

      7/19/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv

      6/14/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Financials

    Live finance-specific insights

    See more
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

      2/9/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer to Acquire Arena Pharmaceuticals

      Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

      12/13/21 6:45:00 AM ET
      $ARNA
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care